INTRODUCTION
============

Irbesartan is an antihypertensive drug and a class C angiotensin II receptor blocker (ARB). It is prescribed for controlling hypertension, as well as for treating heart failure and preventing kidney failure in diabetic and hypertensive patients. Cutaneous side effects to ARB are uncommon^\[[@b1-1128-1-8289-1-10-20190612]\]^. Some have been described, but the mechanisms remain poorly defined in most cases. We describe an exanthematous reaction induced by irbesartan intake through a previously documented immunological mechanism.

CASE DESCRIPTION
================

A 60-year-old female patient was referred to our clinic with a 3-week history of an itchy erythematous maculopapular eruption affecting the torso (thorax and abdomen) and proximal parts of the upper and lower limbs, with lesions resolving with hyperpigmentation ([Fig. 1](#f1-1128-1-8289-1-10-20190612){ref-type="fig"}).

The patient's current medications were atorvastatin, irbesartan, chlordiazepoxide, levothyroxine, estradiol patch, olanzapine and paroxetine. All but irbesartan and paroxetine had been taken for several years. Irbesartan 150 mg daily had been introduced approximately 2 months before the exanthematous rash began and paroxetine had been introduced after the symptoms had appeared. There was no history of any infectious disease.

Histopathological examination of the lesions showed a predominantly lymphocytic infiltrate of the dermis with some eosinophils, compatible with a drug reaction. Allergy work-up included patch tests with irbesartan and candesartan (5% in petrolatum; the latter tested as a possible alternative). A lymphocyte transformation test (LTT) with irbesartan was also performed.

The patch test with irbesartan was positive at 48 and 96 hours, while candesartan was negative. The LTT to irbesartan (100 μg/ml) was positive, showing a stimulation index of 6.3. Irbesartan was switched to diltiazem and new lesions stopped appearing.

Based on clinical and histological findings and the results of patch tests and the LTT, a delayed allergic drug reaction to irbesartan was diagnosed.

Three months later candesartan was introduced into the patient's drug regimen, with no skin reaction after 3 months.

DISCUSSION
==========

There are few reports of skin reactions induced by ARBs, with losartan and valsartan being the most frequent culprits^\[[@b1-1128-1-8289-1-10-20190612]\]^. Two cases due to irbesartan have been described in the literature: one case of multiform erythema with a positive LTT^\[[@b2-1128-1-8289-1-10-20190612]\]^ and one lichenoid eruption with a positive patch test^\[[@b3-1128-1-8289-1-10-20190612]\]^. Vena et al. described a series of eczematoid reactions to angiotensin-converting enzyme inhibitors or ARBs (irbesartan in two cases)^\[[@b4-1128-1-8289-1-10-20190612]\]^. The authors attributed the reactions to a pharmacological mechanism related to interference of the kallikrein-kinin system and elevation of circulating and cutaneous proinflammatory bradykinin, since ARBs can increase bradykinin levels in hypertensive subjects^\[[@b5-1128-1-8289-1-10-20190612]\]^. One case of irbesartan-induced maculopapular exanthema was described by Gambini et al.^\[[@b6-1128-1-8289-1-10-20190612]\]^, presenting as an acute and febrile reaction 5 days after the patient initiated irbesartan. In this case, biopsy showed an interface dermatitis characterized by a predominant upper dermal lymphocytic infiltration, similar to our patient, but no other studies were performed and the mechanism was considered unknown. In our case, the exanthema appeared later, 2 months after irbesartan introduction, and there were no constitutional symptoms. It was clear that an immunological mechanism was involved, so it was classified as an allergic reaction.

Irbesartan and candesartan are benzimidazole derivatives, both having a biphenyl-tetrazole moiety and a substituted imidazole core. Despite the similarity of their chemical structures, cross-reaction did not occur in our patient, with candesartan proving to be a safe alternative.
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